OBJECTIVE: To evaluate the impact of different screening intervals on screening for nasopharyngeal carcinoma (NPC). METHODS: A Markov model was constructed, based on the natural history of NPC. The 5-year mortality rate of NPC was the major measurement to evaluate the efficacies of 16 screening strategies. Parameters for the model were derived from published literature. RESULTS: Screening reduced the 5-year mortality rate for NPC by 20.4 -43.3%, compared with the equivalent rate without screening. The 5year mortality rate and the NPC pick-up rate with strategy A1 (annual screening) were 23.6% and 83.9%, respectively. Compared with strategy A1, strategy B1 (annual screening for seropositive subjects; biennial screening for seronegative subjects) had a similar 5-year mortality rate (24.0%) and a slightly smaller NPC pick-up rate (81.7%), but led to a 39.3% reduction in total screenings. Compared with all other strategies excluding strategy A1, strategy B1 achieved the lowest 5-year mortality rate and the largest NPC pick-up rate. CONCLUSIONS: Strategy B1 had the highest efficacy for NPC screening.
Introduction
Nasopharyngeal carcinoma (NPC) occurs rarely in most parts of the world but its prevalence is high in southeast Asia and China. 1 -5 The reported incidence of NPC in the Chinese population is 10 -40/100 000 per year, 1,6 -8 whereas it is < 6/100 000 per year in North African-Arabic populations 9 and < 0.3/100 000 per year in Japan. 10 Among the Chinese provinces, Guangdong ranks first in terms of the incidence of NPC, as reported by the Chinese Cancer Registry System. 1, 4, 5, 11 Epstein-Barr virus (EBV) infection is strongly associated with the occurrence of NPC, 5,12 -20 and the immunoglobulin (Ig)A antibody against the EBV viral capsid antigen (EBV VCA/IgA) is a widely used antibody a DP Rao and J Gu contributed equally to this work. DP Rao, J Gu, XH Meng et al. Efficacy analysis for NPC screening marker for NPC screening. 21 -25 Studies have shown that screening for NPC is an effective measure for secondary prevention. 6,25 -28 A clinical and serological follow-up study of NPC conducted between 1986 and 2002 in Zhongshan City, Guangdong Province, China, reported that two-thirds of NPC cases could be detected at an early disease stage (i.e. 1997 American Joint Committee of Cancer/International Union Against Cancer tumour-node-metastasis classification system stages I -II), 29, 30 using an EBV VCA/IgA test. 25 The proportion of early-stage NPC cases detected using an EBV VCA/IgA test was significantly higher than the proportion of symptomatic cases detected by the same method (i.e. 67.6% and 19.6%, respectively). 25 Markov processes, as a modelling technique, have been widely applied in evaluations of cancer screening. 31 -33 Only two studies, however, have used simulated models to evaluate screening strategies for NPC. In 1999, Chen et al. 27 constructed a Markov model of the natural history of NPC, using published screening data from the general population of Guangxi Province in China, to predict deaths caused by the disease. The results showed that the mortality rate in patients with NPC who were screened with the EBV VCA/IgA test was sharply reduced (by 30%) compared with the mortality rate in patients who did not receive screening. 27 In 2010, Choi et al. 28 used Markov chain models and reported that the 5-year survival rate for familial NPC with screening varied from 77.7% to 80.1%, which was higher than that observed without screening (67.9%).
Though both studies illustrated that the survival rate of NPC patients would be improved by screening, 27, 28 these findings were based on the assumption that, in the natural history model of NPC, regression from a state of EBV-seropositivity to a state of health was not possible. 27, 28 There is growing evidence, however, that EBV seropositivity can regress to a state of health. 25, 34 One study reported that 10.9% of EBV antibody-positive individuals became EBV antibody-negative, and that 5.4% of EBV-seronegative individuals became EBVseropositive, within 4 years. 34 The screening interval for NPC is a controversial issue that has been inadequately evaluated. Chen et al. 27 27 Choi et al. 28 evaluated four strategies: annual screening; biennial screening; triennial screening; and annual screening for EBV-seropositive subjects plus triennial screening for EBV-seronegative subjects. They found that triennial screening for EBV-seronegative subjects and annual screening for EBV-seropositive subjects had the highest efficacy for NPC screening. 28 Because of the lack of consensus on the appropriate screening interval for NPC, it is necessary to take other screening strategies into account in order to evaluate fully the efficacy of different approaches. Furthermore, validation analyses for the natural history model of NPC and sensitivity analyses were not performed in the previous studies. 27, 28 A Markov model was constructed for the present study that allowed for regression from a state of EBV-seropositivity to a state of health. A validation analysis for the natural history model of NPC and a sensitivity analysis were also performed. In addition, the screening strategies for NPC were altered by using different time intervals and a total of 16 strategies were evaluated.
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Materials and methods
SIMULATION MODEL
To compare the efficacies of different screening strategies for NPC, a Markov simulation model (based on the natural history of NPC) was constructed using SAS software, version 9.2 (SAS Institute, Cary, NC, USA) for Windows ® . The Markov simulation model consisted of two parts: the first part involved simulation of the natural history of NPC among a high-risk population; the second part simulated NPC screening. The simulation followed a cohort of 100 000 individuals as they aged from 30 to 59 years. Each individual would move through the simulation until they ended in the absorbing state. The Markov model is shown in Fig. 1 .
Parameters for simulation (such as EBVseropositive rate, sensitivity and specificity of the EBV VCA/IgA test, 5-year survival rate for NPC and NPC incidence), were sourced from Sihui City in Guangdong Province, China. Annual transition probabilities for the natural history model were obtained from published literature. 27, 34 The 5-year mortality rate, the total number of screens and the NPC pick-up rate were estimated for each strategy in the present study. The NPC pick-up rate was calculated to be the number of detected NPC incidences divided by the total number of NPC incidences. The 5-year mortality rates were based on the 5-year survival rates of screen-detected and symptomatic NPC, as shown in Formula 1. The 5-year survival rates of screen-detected and symptomatic NPC used in the present study were 79.9% and 58.4%, respectively (Formula 1). 35 
NATURAL HISTORY MODEL
The natural history model of NPC was based on a previous study, 27 but also assumed that the state of EBV-positivity could regress to the state of health during the course of a year ( Fig. 1 ). 25, 34 The natural history states of NPC were: health; EBV-seropositive; preclinical but screen-detectable phase (PCDP); and clinical NPC. The state of health indicated that the subject did not have NPC and that EBV antibodies could not be detected in serum. EBV-seropositive indicated that EBV antibodies could be found on serological testing, but that PCDP had not developed. PCDP included individuals in whom NPC was detected, but who were asymptomatic at screening. Clinical NPC described individuals with symptoms of NPC. Subjects in the state of health could remain in the same state or progress to the state of being EBVseropositive. Subjects in the state of EBVseropositivity could remain in the same state, progress to the state of PCDP or regress to the state of health. Subjects in the state of PCDP could remain in the same state or progress to clinical NPC. Clinical NPC was a surrogate endpoint, similar to that used by Chen et al. 27 
PROBABILITIES OF TRANSITION
The probabilities of transition among the states of the natural history model of NPC were obtained in the present study by two different measures. Using the method of Miller and Homan, 36 the annual transition probabilities from health to EBV-seropositive and from EBVseropositive to health were determined from transition rates obtained from the literature. 34 Other annual transition probabilities were obtained from the study by Chen et al. 27 The probabilities are shown in Table 1 . The simulation began with a cohort of 100 000 30year-old subjects who were followed for 30 years (i.e. until age 59). Assumptions were made that, in the initial population, 7.160% of the subjects were in the EBV-seropositive state, 24 0.025% were in the PCDP state 11 and the remainder (92.815%) were in the state of health.
SCREENING STRATEGIES
According to the NPC screening process currently used in Sihui City, EBV status is examined by serological testing against EBV VCA/IgA; any subject identified as being EBV-seropositive then has a nasopharyngeal fibrescope (NPF) examination. If the result of the NPF examination is positive, the subject undergoes a biopsy to diagnose NPC.
The present study compared 16 NPC screening strategies (Table 2) : the screening interval differed in each strategy but other parameters were unchanged. Assumptions were that all subjects complied with the programme, and that the sensitivity and specificity rates of the NPF examination were 98% and 100%, respectively. The sensitivity and specificity rates of the EBV VCA/IgA test were 95% and 90%, respectively. 37
MODEL VALIDATION
Validation of the model involved calibration by comparing the predicted age-specific incidences of NPC with the observed NPC incidences in Sihui City in 2005. 38 Prediction of the age-specific incidences of NPC was based on the natural history model of NPC. Pearson's χ 2 -test was performed to investigate matching between the predicted and observed incidences of NPC in Sihui City: the Sihui Cancer Registry System was established in 1978 and records all cancer patients from each regional hospital in Sihui and from the local clinical oncology departments of the city's hospitals. 35 Since 1987, Sihui City has been one of the epidemiological fields where the Chinese National Programmes for Science and Technology Development has launched initiatives to improve early detection of NPC by serological screening tests.
SENSITIVITY ANALYSES
One-way sensitivity analyses were performed to assess the sensitivity of the mortality rate to changes in screening test sensitivity, screening interval and compliance of the subject.
Results
PREDICTED OUTCOMES
Predicted outcomes are shown in Table 3 . In the case of no screening, the model predicted 1511 cases of NPC in the simulated population of 100 000 adults, which corresponded to a 5-year mortality rate of 41.6%. The 5-year mortality rate for NPC increased, whereas the NPC pick-up rate and the total screens decreased with increasing screening interval (Table 3) . Compared with no screening, all 16 strategies improved life expectancy, with a decrement of > 20% in the 5-year mortality rate (Table 3 ). Strategy A1 (annual screening) achieved the lowest 5year mortality rate (23.6%), the highest NPC pick-up rate (83.9%) and the largest number of total screens (3 081 193). Compared with strategy A1, the 5-year mortality rate with strategy B1 (annual screening for seropositive subjects; biennial screening for seronegative subjects) slightly increased from 23.6% to 24.0% and the NPC pick-up rate slightly decreased from 83.6% to 81.7%; however, the total screens dramatically decreased by 39.3%, from 3 081 193 to 1 870 554. The 5year mortality rate with strategy B1 decreased sharply by 42.3%, from 41.6% to 
A1
Annual screening A2
Biennial screening A3
Triennial screening A4
4-year screening A5
5-year screening A6
6-year screening B1
Annual screening for seropositive subjects; biennial screening for seronegative subjects B2
Annual screening for seropositive subjects; triennial screening for seronegative subjects B3
Annual screening for seropositive subjects; 4-year screening for seronegative subjects B4
Annual screening for seropositive subjects; 5-year screening for seronegative subjects B5
Annual screening for seropositive subjects; 6-year screening for seronegative subjects C1
Annual screening for seronegative subjects; biennial screening for seropositive subjects C2
Annual screening for seronegative subjects; triennial screening for seropositive subjects C3
Annual screening for seronegative subjects; 4-year screening for seropositive subjects C4
Annual screening for seronegative subjects; 5-year screening for seropositive subjects C5
Annual screening for seronegative subjects; 6-year screening for seropositive subjects DP Rao, J Gu, XH Meng et al. Efficacy analysis for NPC screening 24 .0%, compared with no screening. Furthermore, compared with strategy B1, all strategies except strategy A1 resulted in increases in the 5-year mortality rate and decreases in the NPC pick-up rate ( Table 3 ).
MODEL VALIDATION
In the model, the number of predicted NPC incidences rose from 20.7 to a peak of 69.0 per 100 000 per year as the subjects' ages increased from 30 to 59 years (Fig. 2) . In 2005, the number of NPC incidences in Sihui City increased with age, and a peak incidence of 75 per 100 000 per year was observed at age 59. 38 Differences between the predicted NPC incidence and the observed NPC incidence in Sihui City were not statistically significant.
SENSITIVITY ANALYSES
One-way sensitivity analysis was performed to assess the sensitivity of the mortality rate to changes in screening test sensitivity, screening interval and compliance of the subject.
Baseline parameters and assumptions for the model are outlined in Table 4 . When one of the baseline parameters changed, the other parameters were maintained at the baseline level. In this analysis, the model was sensitive to variations in the sensitivity of the EBV VCA/IgA test, screening interval and compliance of the subject.
Decreased sensitivity of the screening test was related to an increase in the 5-year mortality rate (Fig. 3) . Variation in the sensitivity of the screening test from 70% to 99% resulted in an estimated increment of the 5-year mortality rate of 9.7%: the actual 5-year mortality rate went from 24.7% for the highest sensitivity to 27.1% for the lowest sensitivity. The 5-year mortality rate also increased with an increase in the screening interval ( Fig. 4) . Increasing the screening interval from every 1 year to every 6 years, increased the 5-year mortality rate from 25.1% to 34.1%. A decrease in NPC screening compliance resulted in an increase in the 5- 
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year mortality rate, which ranged from 23.6% with 100% compliance to 28.0% for 50% compliance (Fig. 5 ).
Discussion
Previous studies have shown that screening for NPC can significantly reduce the mortality rate associated with this disease, 27, 28, 35 but the impact of screening interval on the efficacy of different screening strategies has not been adequately evaluated. An improved Markov simulation model was developed in the present study, in order to evaluate screening strategies for NPC using different time intervals. All the screening strategies used for NPC in the present study reduced the mortality rate and increased the pick-up rate for NPC. With screening, the 5-year mortality rate for NPC was reduced by 20.4 -43.3% compared with An improved model of the natural history of NPC was constructed successfully. The model in the present study was more complete than those used previously. 27, 28 The present model assumed that the state of EBVseropositivity could regress to the state of health during the course of a year. As validation for the model, the number of predicted NPC incidences in the model was shown to be consistent with the number of incidences observed in Sihui City in 2005. 38 The present study suggested that strategy B1 had the highest efficacy for NPC screening. Using strategy A1 for NPC screening could achieve the lowest 5-year mortality rate and the highest NPC pick-up rate of the 16 strategies evaluated, but resulted in the largest number of screens over a 30-year period. Compared with strategy A1, strategy B1 had a similar 5-year mortality rate (24.0%) and a similar NPC pick-up rate (81.7%). Notably, however, the total number of screens with strategy B1 (1 870 554) was decreased by 39.3% from that for strategy A1 (3 081 193) . Additionally, all of the remaining strategies (excluding A1) led to higher 5-year mortality rates and lower NPC pick-up rates. This suggests that strategy B1 could achieve the highest efficacy for NPC screening. This finding was not consistent with that of a study undertaken in Hong Kong 28 in which four strategies (equivalent to A1, A2, A3 and B2 in the present study) were considered. In the Hong Kong study, strategy B1 was not evaluated, and strategy B2 (annual screening for seropositive subjects; triennial screening for seronegative subjects) had a similar 5-year mortality rate to that of 28 In the present study, the efficacies of strategies A3 (triennial screening) and A6 (6-year screening) were different and did not correspond to those of a previous study published in 1999. 27 The present study found that the impact of screening intervals for EBV-seropositive and EBV-seronegative subjects was different and had a considerable effect on the mortality rate from NPC. When the interval for EBV-seropositive subjects was fixed at 1 year and the interval for EBV-seronegative subjects varied from 2 to 6 years (i.e. strategies B1 to B5), the 5-year mortality rate for NPC increased by 10.0% (from 24.0% to 26.4%), the NPC pick-up rate decreased by 13.7% (from 81.7% to 70.5%) and the total screens decreased by 51.7% (from 1 870 554 to 903 954). When the interval for EBVseronegative subjects was fixed at 1 year and the interval for EBV-seropositive subjects changed from 2 to 6 years (strategies C1 to C5), the 5-year mortality rate for NPC increased by 23.5% (from 26.8% to 33.1%), the NPC pick-up rate decreased by 43.0% (from 69.0% to 39.3%), and the total screens decreased by 29.0% (from 2 593 772 to 1 840 692). These changes showed that, for EBV-seropositive subjects, the impact of screening interval on the 5-year mortality rates and the NPC pick-up rates was stronger than for the EBV-seronegative subjects, and that the impact of intervals for EBVseronegative subjects on the total screens was stronger than for EBV-seropositive subjects. Consequently, to reduce the total The present study suggested that sensitivity of the screening test, screening interval and screening compliance could affect the mortality rate for NPC. In fact, these factors can change the number of patients with NPC who are detected by screening. When the sensitivity of the screening test or the screening compliance was improved, the number of patients detected should increase. A shorter interval should lead to a larger number of patients with NPC being detected by screening and should improve the 5-year survival rate for this disease. With screening, more cases of NPC can be detected at an early disease stage compared with the number detected without screening. 25 -28,39 The effects of treatment are better for early-stage than for advanced NPC; 6, 40 in addition, the survival rate for patients with NPC detected by screening is better than that for patients who present with symptomatic NPC. 26 -28,35,41 As a result, to yield more patients with early-stage NPC, the sensitivity of the screening test and screening compliance should be at a high level and, if resources are sufficient, the screening interval should be as short as possible.
There were some limitations to the present study. First, the predicted outcomes of the 16 screening strategies for NPC were simulated assuming that subject compliance in the screening programme was 100%. Compliance of subjects can impact the efficacy of screening for NPC; in reality, it is difficult to ensure that all participants are complying with a screening programme. 26 Secondly, the parameters of the model, which were sourced from previous studies, should be updated. Although these limitations exist, the findings of the present analysis appear to have important implications for NPC screening programmes.
In conclusion, the present study showed that an improved Markov model for the natural history of NPC was successfully constructed. The findings suggest that strategy B1 -annual screenings for EBVseropositive subjects and biennial screenings for EBV-seronegative subjects -achieved the greatest efficacy among the 16 strategies modelled. Using this strategy, the 5-year mortality rate dropped dramatically (by 42.3%) from 41.6% to 24.0% compared with no screening.
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